(Q30241808)

English

Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 June 2017

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

Europe PubMed Central

Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 June 2017

cardiovascular disease

1 reference

based on heuristic

inferred from title

author name string

Shishi Xu

1

1 reference

Europe PubMed Central

PubMed publication ID

12 June 2017

Xinyue Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

12 June 2017

Lizhi Tang

3

1 reference

Europe PubMed Central

PubMed publication ID

12 June 2017

Fang Zhang

4

1 reference

Europe PubMed Central

PubMed publication ID

12 June 2017

Nanwei Tong

5

1 reference

Europe PubMed Central

PubMed publication ID

12 June 2017

language of work or name

0 references

publication date

4 November 2016

1 reference

Europe PubMed Central

PubMed publication ID

12 June 2017

Postgraduate Medicine

1 reference

Europe PubMed Central

PubMed publication ID

12 June 2017

129

1 reference

Europe PubMed Central

PubMed publication ID

12 June 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

12 June 2017

205-215

1 reference

Europe PubMed Central

PubMed publication ID

12 June 2017

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Combination of Saxagliptin and Metformin Is Effective as Initial Therapy in New-Onset Type 2 Diabetes Mellitus With Severe Hyperglycemia.

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

The Impact of Hypoglycemia on the Cardiovascular System: Physiology and Pathophysiology

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Severe Hypoglycemia and Cardiovascular or All-Cause Mortality in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Severe hypoglycemia and risks of vascular events and death

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Cardiovascular Events in Diabetic and Nondiabetic Adults With or Without History of Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1255537

21 January 2018

Identifiers

10.1080/00325481.2017.1255537

1 reference

Europe PubMed Central

PubMed publication ID

12 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30241808&oldid=1976014538"